Wednesday, September 28, 2016

Dilacor XR


Dilacor XR is a brand name of diltiazem, approved by the FDA in the following formulation(s):


DILACOR XR (diltiazem hydrochloride - capsule, extended release; oral)



  • Manufacturer: WATSON LABS

    Approval date: May 29, 1992

    Strength(s): 120MG [AB2], 180MG [AB2], 240MG [RLD][AB2]

Has a generic version of Dilacor XR been approved?


A generic version of Dilacor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dilacor XR and have been approved by the FDA:


diltiazem hydrochloride capsule, extended release; oral



  • Manufacturer: APOTEX

    Approval date: August 6, 1998

    Strength(s): 240MG [AB2]


  • Manufacturer: APOTEX

    Approval date: December 19, 2000

    Strength(s): 120MG [AB2], 180MG [AB2]


  • Manufacturer: MYLAN

    Approval date: March 18, 1998

    Strength(s): 120MG [AB2], 180MG [AB2], 240MG [AB2]


  • Manufacturer: WATSON LABS FLORIDA

    Approval date: October 10, 1997

    Strength(s): 120MG [AB2], 180MG [AB2], 240MG [AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilacor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Tablets with controlled-rate release of active substances
    Patent 5,422,123
    Issued: June 6, 1995
    Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
    Assignee(s): Jagotec AG
    Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
    Patent expiration dates:

    • June 6, 2012



See also...

  • Dilacor XR 24-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
  • Dilacor XR Consumer Information (Cerner Multum)
  • Dilacor XR Advanced Consumer Information (Micromedex)
  • Diltiazem Consumer Information (Drugs.com)
  • Diltiazem Consumer Information (Wolters Kluwer)
  • Diltiazem 12-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
  • Diltiazem 24-Hour Extended-Release Beads Capsules Consumer Information (Wolters Kluwer)
  • Diltiazem 24-Hour Extended-Release Beads Tablets Consumer Information (Wolters Kluwer)
  • Diltiazem 24-Hour Sustained-Release Beads Capsules Consumer Information (Wolters Kluwer)
  • Diltiazem 24-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
  • Diltiazem Immediate-Release Tablets Consumer Information (Wolters Kluwer)
  • Dilt-CD Consumer Information (Cerner Multum)
  • Diltiazem Consumer Information (Cerner Multum)
  • Dilt-CD Advanced Consumer Information (Micromedex)
  • Diltiazem Advanced Consumer Information (Micromedex)
  • Diltiazem Intravenous Advanced Consumer Information (Micromedex)
  • Diltiazem Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Fenitron




Fenitron may be available in the countries listed below.


Ingredient matches for Fenitron



Phenytoin

Phenytoin sodium salt (a derivative of Phenytoin) is reported as an ingredient of Fenitron in the following countries:


  • Mexico

International Drug Name Search

Posted by at No comments:
Labels:

Fumay




Fumay may be available in the countries listed below.


Ingredient matches for Fumay



Fluconazole

Fluconazole is reported as an ingredient of Fumay in the following countries:


  • Taiwan

International Drug Name Search

Posted by at No comments:
Labels:

Dexilant


Dexilant is a brand name of dexlansoprazole, approved by the FDA in the following formulation(s):


DEXILANT (dexlansoprazole - capsule, delayed release; oral)



  • Manufacturer: TAKEDA PHARMS

    Approval date: January 30, 2009

    Strength(s): 30MG, 60MG [RLD]

Has a generic version of Dexilant been approved?


No. There is currently no therapeutically equivalent version of Dexilant available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dexilant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Benzimidazole compound crystal
    Patent 6,462,058
    Issued: October 8, 2002
    Inventor(s): Akira; Fujishima & Isao; Aoki & Keiji; Kamiyama
    Assignee(s): Takeda Chemical Industries, Ltd.
    A novel crystal of (R)-2-[[[3-methyl-4-(2, 2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
    Patent expiration dates:

    • June 15, 2020
      ✓ 
      Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 15, 2020
      ✓ 
      Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 15, 2020
      ✓ 
      Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • December 15, 2020
      ✓ 
      Pediatric exclusivity




  • Benzimidazole compound crystal
    Patent 6,664,276
    Issued: December 16, 2003
    Inventor(s): Akira; Fujishima & Isao; Aoki & Keiji; Kamiyama
    Assignee(s): Takeda Chemical Industries, Ltd.
    A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
    Patent expiration dates:

    • June 15, 2020
      ✓ 
      Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 15, 2020
      ✓ 
      Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 15, 2020
      ✓ 
      Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • December 15, 2020
      ✓ 
      Pediatric exclusivity




  • Benzimidazole compound crystal
    Patent 6,939,971
    Issued: September 6, 2005
    Inventor(s): Fujishima; Akira & Aoki; Isao & Kamiyama; Keiji
    Assignee(s): Takeda Pharmaceutical Company, Ltd.
    A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
    Patent expiration dates:

    • June 15, 2020
      ✓ 
      Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS


    • June 15, 2020
      ✓ 
      Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS


    • June 15, 2020
      ✓ 
      Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS


    • December 15, 2020
      ✓ 
      Pediatric exclusivity




  • Process for the crystallization of (R)- or (S)-lansoprazole
    Patent 7,285,668
    Issued: October 23, 2007
    Inventor(s): Hashimoto; Hideo & Urai; Tadashi
    Assignee(s): Takeda Pharmaceutical Company Limited
    The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0° C. to about 35° C. from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.
    Patent expiration dates:

    • June 15, 2020
      ✓ 
      Drug substance


    • December 15, 2020
      ✓ 
      Pediatric exclusivity




  • Controlled release preparation
    Patent 7,790,755
    Issued: September 7, 2010
    Inventor(s): Akiyama; Yohko & Kurasawa; Takashi & Bando; Hiroto & Nagahara; Naoki
    Assignee(s): Takeda Pharmaceutical Company Limited
    A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
    Patent expiration dates:

    • August 2, 2026
      ✓ 
      Drug product


    • February 2, 2027
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 30, 2012 - NEW PRODUCT

    • July 30, 2012 - PEDIATRIC EXCLUSIVITY

See also...

  • Dexilant Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Dexilant Consumer Information (Cerner Multum)
  • Dexilant Advanced Consumer Information (Micromedex)
  • Dexlansoprazole Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Dexlansoprazole Consumer Information (Cerner Multum)
  • Dexlansoprazole Advanced Consumer Information (Micromedex)
  • Dexlansoprazole AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Demadex


Demadex is a brand name of torsemide, approved by the FDA in the following formulation(s):


DEMADEX (torsemide - tablet; oral)



  • Manufacturer: MEDA PHARMS

    Approval date: August 23, 1993

    Strength(s): 100MG [AB], 10MG [AB], 20MG [RLD][AB], 5MG [AB]

Has a generic version of Demadex been approved?


Yes. The following products are equivalent to Demadex:


torsemide tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: May 31, 2005

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: October 17, 2007

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: HETERO DRUGS

    Approval date: January 27, 2009

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: PAR PHARM

    Approval date: May 27, 2003

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: PLIVA PHARM IND

    Approval date: May 30, 2003

    Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: PLIVA PHARM IND

    Approval date: October 19, 2004

    Strength(s): 100MG [AB]


  • Manufacturer: ROXANE

    Approval date: March 1, 2005

    Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: SUN PHARM INDS

    Approval date: February 26, 2008

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: TEVA

    Approval date: May 14, 2002

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: VINTAGE PHARMS

    Approval date: March 22, 2011

    Strength(s): 100MG [AB], 10MG [AB], 20MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Demadex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Demadex.

See also...

  • Demadex Consumer Information (Wolters Kluwer)
  • Demadex Solution Consumer Information (Wolters Kluwer)
  • Demadex Consumer Information (Cerner Multum)
  • Demadex Advanced Consumer Information (Micromedex)
  • Demadex Intravenous Advanced Consumer Information (Micromedex)
  • Demadex AHFS DI Monographs (ASHP)
  • Torsemide Consumer Information (Wolters Kluwer)
  • Torsemide Solution Consumer Information (Wolters Kluwer)
  • Torsemide Consumer Information (Cerner Multum)
  • Torsemide Advanced Consumer Information (Micromedex)
  • Torsemide Intravenous Advanced Consumer Information (Micromedex)
  • Torsemide AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Drisdol


Drisdol is a brand name of ergocalciferol, approved by the FDA in the following formulation(s):


DRISDOL (ergocalciferol - capsule; oral)



  • Manufacturer: SANOFI AVENTIS US

    Approved Prior to Jan 1, 1982

    Strength(s): 50,000 IU [RLD][AA]

Has a generic version of Drisdol been approved?


Yes. The following products are equivalent to Drisdol:


ergocalciferol capsule; oral



  • Manufacturer: ORIT LABS LLC

    Approval date: May 20, 2009

    Strength(s): 50,000 IU [AA]


  • Manufacturer: SIGMAPHARM LABS LLC

    Approval date: July 14, 2010

    Strength(s): 50,000 IU [AA]


  • Manufacturer: STRIDES ARCOLAB LTD

    Approval date: August 3, 2010

    Strength(s): 50,000 IU [AA]


  • Manufacturer: SUN PHARM INDS INC

    Approval date: December 29, 2009

    Strength(s): 50,000 IU [AA]

VITAMIN D (ergocalciferol capsule; oral)



  • Manufacturer: BANNER PHARMACAPS

    Approved Prior to Jan 1, 1982

    Strength(s): 50,000 IU [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Drisdol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Drisdol.

See also...

  • Drisdol Consumer Information (Wolters Kluwer)
  • Drisdol Solution Consumer Information (Wolters Kluwer)
  • Drisdol Consumer Information (Cerner Multum)
  • Drisdol AHFS DI Monographs (ASHP)
  • Ergocalciferol Consumer Information (Wolters Kluwer)
  • Ergocalciferol Solution Consumer Information (Wolters Kluwer)
  • Vitamin D Consumer Information (Cerner Multum)
  • Ergocalciferol Consumer Information (Cerner Multum)
  • Ergocalciferol AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Demerol


Demerol is a brand name of meperidine, approved by the FDA in the following formulation(s):


DEMEROL (meperidine hydrochloride - injectable; injection)



  • Manufacturer: HOSPIRA

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG/ML [RLD][AP], 25MG/ML [RLD][AP], 50MG/ML [RLD][AP], 75MG/ML [RLD][AP]

DEMEROL (meperidine hydrochloride - tablet; oral)



  • Manufacturer: SANOFI AVENTIS US

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG [RLD][AA], 50MG [RLD][AA]

Has a generic version of Demerol been approved?


Yes. The following products are equivalent to Demerol:


meperidine hydrochloride injectable; injection



  • Manufacturer: BAXTER HLTHCARE CORP

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG/ML [AP], 25MG/ML [AP], 50MG/ML [AP], 75MG/ML [AP]


  • Manufacturer: ELKINS SINN

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG/ML [AP], 25MG/ML [AP], 50MG/ML [AP], 75MG/ML [AP]


  • Manufacturer: WATSON LABS

    Approval date: March 17, 1992

    Strength(s): 100MG/ML [AP], 50MG/ML [AP]

meperidine hydrochloride tablet; oral



  • Manufacturer: BARR

    Approval date: July 2, 1984

    Strength(s): 50MG [AA]


  • Manufacturer: BARR

    Approval date: September 19, 1984

    Strength(s): 100MG [AA]


  • Manufacturer: CARACO

    Approval date: August 8, 2002

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: EPIC PHARMA

    Approval date: May 28, 1999

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: MALLINCKRODT

    Approval date: June 13, 2000

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: MIKART

    Approval date: June 24, 2009

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: ROXANE

    Approval date: March 12, 1997

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: VINTAGE PHARMS

    Approval date: December 17, 1998

    Strength(s): 100MG [AA], 50MG [AA]


  • Manufacturer: WATSON LABS

    Approval date: June 30, 1997

    Strength(s): 100MG [AA], 50MG [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Demerol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Demerol.

See also...

  • Demerol Consumer Information (Drugs.com)
  • Demerol Consumer Information (Wolters Kluwer)
  • Demerol Syrup Consumer Information (Wolters Kluwer)
  • Demerol Tablets Consumer Information (Wolters Kluwer)
  • Demerol HCl Consumer Information (Cerner Multum)
  • Demerol Advanced Consumer Information (Micromedex)
  • Demerol Injection Advanced Consumer Information (Micromedex)
  • Demerol AHFS DI Monographs (ASHP)
  • Meperidine Consumer Information (Wolters Kluwer)
  • Meperidine Syrup Consumer Information (Wolters Kluwer)
  • Meperidine Tablets Consumer Information (Wolters Kluwer)
  • Meperidine Consumer Information (Cerner Multum)
  • Meperidine Advanced Consumer Information (Micromedex)
  • Meperidine Injection Advanced Consumer Information (Micromedex)
  • Meperidine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)